Management of breast cancer - Part II

BMJ

Volumn 337, Issue 7662, 2008, Pages 164-169

  Turner, Nicholas C ^a,b   Jones, Alison L ^b,c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; LAPATINIB; PACLITAXEL; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; VITAMIN D; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADVANCED CANCER; ARTHRALGIA; BONE ATROPHY; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; DRUG METABOLISM; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; GENE EXPRESSION PROFILING; HEART DISEASE; HEART INJURY; HOT FLUSH; HUMAN; LEUKEMIA; METASTASIS; MONOTHERAPY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMIC THERAPY; THROMBOEMBOLISM; TREATMENT DURATION; VAGINA BLEEDING; VAGINA DISCHARGE; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CLASSIFICATION; FEMALE; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN;

EID: 47849098038     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a540     Document Type: Review

References (31)

1. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008;26:798-805.
4. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
5. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
6. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
7. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-27.
8. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-7.
9. Bundred NJ, Campbell ID, Davidson N, Deboer RH, Eidtmann H, Monnier A, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008;112:1001-10.
10. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship Between Quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008;26(7):1059-65.
11. Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444-7.
12. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007;25:3837-45.
13. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93.
14. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
15. Cuzick J. Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial. Breast Cancer Research and Treatment 2007;106(suppl 1):abstract 2069.
16. Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 2007;99:516-25.
17. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000;355:1757-70.
18. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
19. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group trial 6a. J Natl Cancer Inst 2007;99:1845-53.
20. Peto R, Davies C, on Behalf of the ATLAS Collaboration. ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women - preliminary results. Breast Cancer Res Treat 2007;106(suppl 1):abstract 48.
21. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
22. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
23. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
24. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
25. Ma XJ, Wang Z, Ryan PD, lsakoff SJ, BarmettlerA, Fuller A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.
26. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
27. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26:736-44.
28. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
29. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007;357:94-5.
30. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
31. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.